GLPwatch
Papers (10386)
Page 134 of 174, ranked by citation count.
- Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.
- Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective.
- Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide).
- Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population.
- [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK].
- Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats.
- Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: a post-hoc analysis of LEADER and SUSTAIN-6 trials.
- Understanding the Benefit of Combining GLP-1 Agonists With Exercise: Time Will Tell.
- Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.
- Recurrent weight gain after sleeve gastrectomy: conversion to Roux-en-Y gastric bypass versus novel GLP-1 s.
- Differential effects of liraglutide naltrexone/bupropion, and caloric restriction on metabolic parameters and beta-cell regeneration in type 2 diabetic rat model: role of beta arrestin 1.
- Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents.
- Unveiling the Therapeutic Potential of Dulaglutide in Mitigating Tacrolimus-Induced Nephrotoxicity Through Targeting the miR-22/HMGB-1/TLR4/MyD88/NF-κB Trajectory.
- Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.
- Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms.
- Efficacy of liraglutide as a follow-up therapy after resolution of glucotoxicity with intensive insulin therapy.
- Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.
- The effects of liraglutide on expressions of insulin secretion and beta cell survive associated GPCR genes in pancreatic beta cells.
- Exenatide and Metformin Improve Serum Indices and Intestinal Flora in patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.
- Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus.
- [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
- Long-Term Clinical and Economic Effects of Switching to Once-Weekly Semaglutide from Other GLP-1 RAs Among Patients with Type 2 Diabetes in China: A Modeling Projection Study.
- Insulins for type 2 diabetes.
- Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN study.
- Assessment of complex treatment influence on systemic inflammation in overweight type 2 diabetes patients.
- Comparative Efficacy and Safety of Oral Semaglutide in Asians and Non-Asians Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
- Efficacy and safety of exenatide once weekly: an overview of the DURATION trials.
- GLP-1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models.
- Endocrine and metabolic effects of Glucagon like peptide 1 receptor agonists (GLP1RA).
- Clinical Effectiveness of Oral Semaglutide in Women with Type 2 Diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Women_ENDO2S-RWD Substudy).
- Exploring the neuroprotective role of GLP-1 agonists against Alzheimer's disease: Real-world evidence from a propensity-matched cohort.
- Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of Their Body Weight Over 72 Weeks.
- Research digest.
- Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials.
- Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Obesity Treatment: A Focus on Pharmacotherapy of Weight Management.
- Liraglutide innovations: a comprehensive review of patents (2014-2024).
- Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
- Exacerbation of Postural Orthostatic Tachycardia Syndrome With Tirzepatide Prescribed for Weight Loss.
- Problematic Pharmacokinetics: A Case of Recurrent Pancreatitis Post Discontinuation of a Glucagon-Like Peptide 1 Receptor Agonists.
- SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes.
- Clinical Efficacy and Safety of Anti-Obesity Medications Among Adult East Asian People with Obesity: A Systematic Literature Review and Indirect Treatment Comparison.
- Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes.
- Semaglutide in NASH-related cirrhosis: still a long way to go?
- [Liraglutide: new results in the treatment of type 2 diabetes mellitus].
- One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction.
- In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis.
- The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
- Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature.
- Effects of Liraglutide on Leptin Promoter Methylation in Ovarian Granulosa Cells of Patients with Polycystic Ovary Syndrome and Obesity.
- Glucagon-like peptide-1 agonists.
- Editorial commentary: Weight loss for cardiovascular disease prevention - is semaglutide the answer?
- Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach.
- Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity.
- Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide.
- Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials.
- Differentiation of Microencapsulated Neonatal Porcine Pancreatic Cell Clusters in Vitro Improves Transplant Efficacy in Type 1 Diabetes Mellitus Mice.
- Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
- Effects of exenatide in a morbidly obese patient with type 2 diabetes.
- Liraglutide in clinical practice: Glycemic control, and predictors of good response.